Back to News
Market Impact: 0.42
Novartis' Del-Desiran Misses Primary Endpoint In Phase 3 DM1 Study; Stock Down 12%
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Novartis reported that its Phase 3 HARBOR trial of del-desiran in myotonic dystrophy type 1 failed to meet the primary endpoint of video hand opening time (vHOT). The failed late-stage study is a material setback for the program and could pressure Novartis shares, though the article provides no additional efficacy, safety, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.58
Ticker Sentiment
NVS-0.85
More News
- Newamsterdam Pharma stock hits 52-week low at 19.57 USD
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage